Lo M, Liu K L, Lantelme P, Sassard J
Département de Physiologie et Pharmacologie Clinique, Centre National de la Recherche Scientifique, URA 1483, Faculté de Pharmacie, Lyon, France.
J Clin Invest. 1995 Mar;95(3):1394-7. doi: 10.1172/JCI117792.
Angiotensin II recognizes two receptor subtypes, AT1 and AT2, both of them having been recently cloned. Although AT2 receptors represent 5-10% of angiotensin II receptors in the kidneys of adult rats, their function remains unknown. In the present work, we examined the possible contribution of AT2 receptors to the regulation of pressure-natriuresis in anesthetized rats infused either with the specific AT2 antagonist PD 123319, or with CGP 42112B, an AT2 ligand with agonistic properties. The effects of PD 123319 were examined in a preparation with stable levels of angiotensin II, and in which AT1 receptors were blocked by the specific antagonist losartan. The effects of CGP 42112B were studied in rats deprived of endogenous angiotensin II. AT2 receptor blockade with PD 123319 did not change the renal blood flow while it increased the diuresis and natriuresis. These effects persisted even after full AT1 receptor blockade with losarfan. CGP 42112B did not modify the renal blood flow, but dose-dependently decreased urine flow and natriuresis. These results show that, contrary to AT1 receptors, renal AT2 receptors have no effect on total renal blood flow, but blunt the pressure-natriuresis, thus demonstrating that this receptor subtype is involved in a function of importance for body fluid and blood pressure regulation.
血管紧张素II可识别两种受体亚型,即AT1和AT2,两者最近均已被克隆。尽管在成年大鼠肾脏中,AT2受体占血管紧张素II受体的5% - 10%,但其功能仍不清楚。在本研究中,我们研究了AT2受体对麻醉大鼠压力-利钠作用调节的可能贡献,这些大鼠分别注射特异性AT2拮抗剂PD 123319或具有激动特性的AT2配体CGP 42112B。在血管紧张素II水平稳定且AT1受体被特异性拮抗剂氯沙坦阻断的实验准备中,研究了PD 123319的作用。在去除内源性血管紧张素II的大鼠中,研究了CGP 42112B的作用。用PD 123319阻断AT2受体并不会改变肾血流量,但会增加利尿和利钠作用。即使在用氯沙坦完全阻断AT1受体后,这些作用仍然持续存在。CGP 42112B不会改变肾血流量,但会剂量依赖性地减少尿流量和利钠作用。这些结果表明,与AT1受体相反,肾AT2受体对总肾血流量没有影响,但会减弱压力-利钠作用,从而证明该受体亚型参与了对体液和血压调节至关重要的功能。